PS1 Update: US FDA IND Submitted for Phase 2 Type 2 Diabetes Trial

Pharmasaga (Taiwan Emerging Stock Market: 7878) announced on October 1 that it has completed the submission of an Investigational New Drug (IND) application to the US FDA for PS1-II-201, a Phase 2 clinical trial of PS1 on type 2 diabetes. 

The company has completed its Phase 1 trial.

PS1 is a first-in-class, small-molecule PDIA4 inhibitor, with a mechanism centered on preserving pancreatic islet cells.

For teams working in metabolic disease: what do you see as the most important considerations when moving a program from Phase 1 to Phase 2